CLINICAL EFFICACY OF INDIVIDUALIZED THERAPY BASED ON INFLAMMATORY BIOMARKERS (IL-6, TNF-α) IN CHRONIC HEART FAILURE

Chronic heart failure (CHF) is a clinical syndrome characterized by a progressive decline in cardiac function, leading to high rates of disability and mortality. In recent years, the leading role of inflammatory processes in its pathogenesis has been established, and the clinical significance of cytokines such as IL-6 and TNF-α is being extensively studied. This study analyzes the effectiveness of individualizing treatment strategies based on the levels of these biomarkers. The results revealed that an individualized approach not only normalizes laboratory parameters but also demonstrates a significant advantage in improving cardiac function, alleviating symptoms, and reducing the risk of rehospitalization.